Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. more
Time Frame | CTNM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.26% | 0.31% | -1.26% |
1-Month Return | -6.52% | 0.6% | -4.16% |
3-Month Return | -22.42% | -9.44% | -0.46% |
6-Month Return | -39.19% | -5.15% | 3.58% |
1-Year Return | -20.19% | 0.33% | 22.47% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | 50.00M | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Cost of Revenue | - | 329.00K | 195.00K | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.27,"profit":true}] | ||
Gross Profit | - | (329.00K) | 50.00M | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-0.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Margin | - | (Infinity%) | 100.00% | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Expenses | 28.65M | 22.39M | 33.92M | [{"date":"2021-12-31","value":84.45,"profit":true},{"date":"2022-12-31","value":66.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (28.65M) | (22.72M) | 16.08M | [{"date":"2021-12-31","value":-178.19,"profit":false},{"date":"2022-12-31","value":-141.32,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Total Non-Operating Income/Expense | (609.00K) | (1.16M) | 11.49M | [{"date":"2021-12-31","value":-5.3,"profit":false},{"date":"2022-12-31","value":-10.09,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Pre-Tax Income | (29.00M) | (24.25M) | 23.17M | [{"date":"2021-12-31","value":-125.17,"profit":false},{"date":"2022-12-31","value":-104.67,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income Taxes | 241.00K | - | 450.00K | [{"date":"2021-12-31","value":53.56,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income After Taxes | (29.24M) | - | 22.72M | [{"date":"2021-12-31","value":-128.71,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income From Continuous Operations | (29.00M) | (24.25M) | 22.72M | [{"date":"2021-12-31","value":-127.65,"profit":false},{"date":"2022-12-31","value":-106.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (29.00M) | (24.25M) | 22.72M | [{"date":"2021-12-31","value":-127.65,"profit":false},{"date":"2022-12-31","value":-106.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
EPS (Diluted) | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
CTNM | |
---|---|
Cash Ratio | 36.84 |
Current Ratio | 37.06 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CTNM | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CTNM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CTNM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.27 |
Price/FCF | NM |
EV/R | 8.25 |
EV/Ebitda | 20.76 |
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) share price today is $12.77
Yes, Indians can buy shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) on Vested. To buy Contineum Therapeutics, Inc. Class A Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTNM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) via the Vested app. You can start investing in Contineum Therapeutics, Inc. Class A Common Stock (CTNM) with a minimum investment of $1.
You can invest in shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) via Vested in three simple steps:
The 52-week high price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $22. The 52-week low price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $12.33.
The price-to-earnings (P/E) ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is
The price-to-book (P/B) ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 2.27
The dividend yield of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 0.00%
The market capitalization of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $329.18M
The stock symbol (or ticker) of Contineum Therapeutics, Inc. Class A Common Stock is CTNM